Skip to main content
OpenTrials

Clinical trial condition

Carcinoma

Explore clinical trials studying Carcinoma. Study availability and eligibility vary by location and protocol.

8,894 public trials 2,121 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma trial results

Active, not recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

NCT06009861

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +7 more
Locations
  • Peking University School and Hospital Stomatology Beijing, Beijing Municipality, China
  • Affiliated Hospital of Hebei University Baoding, Hebei, China
  • Tangshan People's Hospital Tangshan, Hebei, China
  • The First Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang, China
View all 13 locations
View Trial Details
Active, not recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

NCT05219318

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • CH de la Cote Basque - Service d'Oncologie Bayonne, France
  • CHU de Bordeaux - Service d'Oncologie Bordeaux, France
  • Centre François Baclesse - Service d'Oncologie Caen, France
  • Centre Jean Perrin - Service d'Oncologie Clermont-Ferrand, France
View all 26 locations
View Trial Details
Active, not recruiting

Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma

NCT04791735

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Chirurgie Digestive - CHU Amiens Amiens, France
  • Chirurgie viscérale et digestive - CHU Besançon Besançon, France
  • Chirurgie Hépatologie - Hôpital Beaujon Clichy, France
  • Chirurgie Digestive et Hépatobiliaire - Hôpital Henri-Mondor Créteil, France
View all 17 locations
View Trial Details
Active, not recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935

Conditions
Adenocarcinoma, Advanced Solid Tumors Cancer, Breast Diseases, +28 more
Locations
  • Highlands Oncology Group, PA /ID# 218942 Springdale, Arkansas, United States
  • City of Hope National Medical Center /ID# 265620 Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center /ID# 270785 Irvine, California, United States
  • Yale University School of Medicine /ID# 208356 New Haven, Connecticut, United States
View all 64 locations
View Trial Details

Related conditions